Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored
by AstraZeneca Investment(China)Co., LTD. to evaluate the efficacy and safety of Savolitinib
combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC
patients with MET alteration.